As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Company is investing more than €100 million in the expansion of the Halle site
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
